Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Colorectal Neoplasms
  • Drug Resistance, Neoplasm
  • Receptor, IGF Type 1

abstract

  • IMC-A12 alone or in combination with cetuximab was insufficient to warrant additional study in patients with colorectal cancer refractory to EGFR inhibitors.

publication date

  • September 20, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3296668

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.30.4154

PubMed ID

  • 20713879

Additional Document Info

start page

  • 4240

end page

  • 6

volume

  • 28

number

  • 27